- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Immuneering submitted a meeting request to the FDA regarding its therapies.
3 reports, 2 independent
Updated Aug 1
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immuneering submitted a meeting request to the FDA regarding its therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approves new second-line treatment from Immuneering Corporation.1 source
Immuneering is headquartered in Cambridge, MA.1 source
Immuneering requested a meeting with the FDA on August 14, 2025.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Immuneering (United States)
company in Cambridge, United States
Nothing else this week.
- FDA
Related events
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireImmuneering Announces $25 Million Private Placement CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping ca
- GlobeNewswireImmuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treate